Literature DB >> 14634862

Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats.

Mitsuru Okada1, Hidehiko Yanagida, Hiroaki Kuwajima, Tsukasa Takemura.   

Abstract

Treatment with hydroxymethylglutaryl coenzyme A reductase inhibitors and thiazolidinedione derivatives may prevent the development of diabetic nephropathy. The precise mechanisms of the beneficial effects of these agents in mesangial cells are uncertain. We cultured mesangial cells from Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model for human type 2 diabetes mellitus. The effects of fluvastatin and/or troglitazone on DNA synthesis were determined. Fluvastatin in combination with troglitazone markedly inhibited DNA synthesis and induced apoptosis in mesangial cells from OLETF rats. Combined therapy with fluvastatin and thiazolidinedione derivatives may be effective for suppression of mesangial cell proliferation in the early phase of diabetes, thereby possibly slowing the evolution of diabetic glomerulopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634862     DOI: 10.1007/s00467-003-1306-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  60 in total

1.  Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.

Authors:  R Baetta; E Donetti; C Comparato; M Calore; A Rossi; C Teruzzi; R Paoletti; R Fumagalli; M R Soma
Journal:  Pharmacol Res       Date:  1997-08       Impact factor: 7.658

2.  Glomerular size and structure in diabetes mellitus. I. Early abnormalities.

Authors:  R Osterby; H J Gundersen
Journal:  Diabetologia       Date:  1975-06       Impact factor: 10.122

3.  A novel antidiabetic drug, troglitazone--reason for hope and concern.

Authors:  H Imura
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

4.  The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells.

Authors:  T Takemura; S Kondo; T Homma; M Sakai; R C Harris
Journal:  J Biol Chem       Date:  1997-12-05       Impact factor: 5.157

Review 5.  Regulation of mesangial cell proliferation by the mevalonate pathway.

Authors:  Z A Massy; C Guijarro; M P O'Donnell; B L Kasiske; W F Keane
Journal:  Contrib Nephrol       Date:  1997       Impact factor: 1.580

6.  Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.

Authors:  B L Kasiske; M P O'Donnell; W J Garvis; W F Keane
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

7.  Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.

Authors:  G Jerums; T J Allen; C Tsalamandris; A Akdeniz; A Sinha; R Gilbert; M E Cooper
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

8.  Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells.

Authors:  N Takahashi; T Okumura; W Motomura; Y Fujimoto; I Kawabata; Y Kohgo
Journal:  FEBS Lett       Date:  1999-07-16       Impact factor: 4.124

9.  Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells.

Authors:  K Yasunari; M Kohno; H Kano; K Yokokawa; M Minami; J Yoshikawa
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

Review 10.  Bcl-2: a repressor of lymphocyte death.

Authors:  S J Korsmeyer
Journal:  Immunol Today       Date:  1992-08
View more
  2 in total

1.  Inhibitory effects of NO-fluvastatin on proliferation of human lens epithelial cells in vitro by modulating cell cycle regulatory proteins.

Authors:  Zhi Wang; Ruiying Gao; Qianqian Shi; Yukan Huang; Wen Chen; Kaiying Shi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

2.  PPARgamma in Kidney Physiology and Pathophysiology.

Authors:  Eva Kiss-Tóth; Tamás Roszer
Journal:  PPAR Res       Date:  2009-03-10       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.